Lethal	lethal	O	O	O	O
anuria	anuria	O	DISEASE	OTHERS	I
complicating	complicating	O	O	O	O
high	high	O	O	O	O
dose	dose	O	O	O	O
ifosfamide	ifosfamide	CHEMICALS	O	OTHERS	I
chemotherapy	chemotherapy	O	O	O	O
in	in	O	O	O	O
a	a	O	O	O	O
breast	breast	O	DISEASE	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
patient	patient	O	O	O	O
with	with	O	O	O	O
an	an	O	O	O	O
impaired	impaired	O	O	OTHERS	I
renal	renal	O	O	OTHERS	I
function	function	O	O	OTHERS	I
.	.	O	O	O	O

A	a	O	O	O	O
sixty-year-old	sixty-year-old	O	O	O	O
woman	woman	O	O	O	O
with	with	O	O	O	O
advanced	advanced	O	O	O	O
breast	breast	O	DISEASE	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
,	,	O	O	O	O
previously	previously	O	O	O	O
treated	treated	O	O	O	O
with	with	O	O	O	O
cisplatin	cisplatin	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
developed	developed	O	O	O	O
an	an	O	O	O	O
irreversible	irreversible	O	O	O	O
lethal	lethal	O	O	O	O
renal	renal	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
with	with	O	O	O	O
anuria	anuria	O	DISEASE	OTHERS	I
,	,	O	O	O	O
the	the	O	O	O	O
day	day	O	O	O	O
after	after	O	O	O	O
5	5	O	O	O	O
g/m2	g/m2	O	O	O	O
bolus	bolus	O	O	O	O
ifosfamide	ifosfamide	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

Postrenal	postrenal	O	O	OTHERS	I
failure	failure	O	O	OTHERS	I
was	was	O	O	O	O
excluded	excluded	O	O	O	O
by	by	O	O	O	O
echography	echography	O	O	O	O
.	.	O	O	O	O

A	a	O	O	O	O
prerenal	prerenal	O	O	O	O
component	component	O	O	O	O
could	could	O	O	O	O
have	have	O	O	O	O
contributed	contributed	O	O	O	O
to	to	O	O	O	O
renal	renal	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
because	because	O	O	O	O
of	of	O	O	O	O
a	a	O	O	O	O
transient	transient	O	O	O	O
hypotension	hypotension	O	DISEASE	OTHERS	I
,	,	O	O	O	O
due	due	O	O	O	O
to	to	O	O	O	O
an	an	O	O	O	O
increasing	increasing	O	O	O	O
ascitis	ascitis	O	O	O	O
,	,	O	O	O	O
occurring	occurring	O	O	O	O
just	just	O	O	O	O
before	before	O	O	O	O
anuria	anuria	O	DISEASE	OTHERS	I
.	.	O	O	O	O

However	however	O	O	O	O
,	,	O	O	O	O
correction	correction	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
hemodynamic	hemodynamic	O	O	O	O
parameters	parameters	O	O	O	O
did	did	O	O	O	O
not	not	O	O	O	O
improve	improve	O	O	O	O
renal	renal	O	O	O	O
function	function	O	O	O	O
.	.	O	O	O	O

Ifosfamide	ifosfamide	CHEMICALS	O	OTHERS	I
is	is	O	O	O	O
a	a	O	O	O	O
known	known	O	O	O	O
nephrotoxic	nephrotoxic	O	DISEASE	OTHERS	I
drug	drug	O	O	O	O
with	with	O	O	O	O
demonstrated	demonstrated	O	O	O	O
tubulopathies	tubulopathies	O	O	OTHERS	I
.	.	O	O	O	O

We	we	O	O	O	O
strongly	strongly	O	O	O	O
suspect	suspect	O	O	O	O
that	that	O	O	O	O
this	this	O	O	O	O
lethal	lethal	O	O	O	O
anuria	anuria	O	DISEASE	OTHERS	I
was	was	O	O	O	O
mainly	mainly	O	O	O	O
due	due	O	O	O	O
to	to	O	O	O	O
ifosfamide	ifosfamide	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
occurring	occurring	O	O	O	O
in	in	O	O	O	O
a	a	O	O	O	O
patient	patient	O	O	O	O
having	having	O	O	O	O
received	received	O	O	O	O
previous	previous	O	O	O	O
cisplatin	cisplatin	CHEMICALS	O	OTHERS	I
chemotherapy	chemotherapy	O	O	O	O
and	and	O	O	O	O
with	with	O	O	O	O
poor	poor	O	O	O	O
kidney	kidney	O	O	O	O
perfusion	perfusion	O	O	O	O
due	due	O	O	O	O
to	to	O	O	O	O
transient	transient	O	O	O	O
hypotension	hypotension	O	DISEASE	OTHERS	I
.	.	O	O	O	O

We	we	O	O	O	O
recommend	recommend	O	O	O	O
careful	careful	O	O	O	O
use	use	O	O	O	O
of	of	O	O	O	O
ifosfamide	ifosfamide	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
patients	patients	O	O	O	O
pretreated	pretreated	O	O	O	O
with	with	O	O	O	O
nephrotoxic	nephrotoxic	O	DISEASE	OTHERS	I
chemotherapy	chemotherapy	O	O	O	O
and	and	O	O	O	O
inadequate	inadequate	O	O	O	O
renal	renal	O	O	O	O
perfusion	perfusion	O	O	O	O
.	.	O	O	O	O

